Clinical Trials on Myoclonic Epilepsies, Progressive

Total 1913 results

Autifony Therapeutics Limited

Recruiting

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK (AUT022201)

Myoclonus Epilepsies, Progressive

United States
University of Turku

Unknown

Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type

Unverricht-Lundborg Syndrome

Finland
University College, London
University of North Carolina, Chapel Hill; NYU Grossman School of Medicine

Recruiting

Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study (DRPLA NHBS)

Dentatorubral-Pallidoluysian Atrophy

United States, United Kingdom
Lars Bo Andersen

Unknown

Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy (EFA)

Epilepsy | Seizure Disorder | Epileptic Seizures | Epilepsia

Denmark
Parasail, LLC

Available

Intravenous VAL-1221 Lafora Expanded Access Protocol (LEAP)

Lafora Disease
Ionis Pharmaceuticals, Inc.

Completed

Natural History and Functional Status Study of Patients With Lafora Disease

Lafora Disease

United States, Italy, Spain
Azienda Socio Sanitaria Territoriale di Mantova

Unknown

Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

Unverricht-Lundborg Disease
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Unverricht-Lundborg Disease

United States, Canada, Finland, France, Israel, Russian Federation, Serbia, Tunisia
National Institute of Neurological Disorders and...

Completed

Ketogenic Diet in Lafora Disease

Lafora Disease

United States
King's College London
King's College Hospital NHS Trust; Charles University, Czech Republic; Hopital... and other collaborators

Recruiting

Biology of Juvenile Myoclonic Epilepsy (BIOJUME)

Juvenile Myoclonic Epilepsy

United States, Canada, Czechia, Denmark, Estonia, France, Italy, Norway, United Kingdom
University of British Columbia

Terminated

Flunarizine for Treatment Resistant Absence Epilepsy

Juvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence Epilepsy

Canada
National Institute of Neurological Disorders and...

Completed

Effect of Levetiracetam on Brain Excitability

Healthy | Myoclonic Epilepsy

United States
Rawalpindi Medical College

Completed

Effect of Pretreatment of Lignocaine Versus Midazolam in Prevention of Etomidate Induced Myoclonus.

Myoclonic Jerk
Universiteit Antwerpen
Universitaire Ziekenhuizen KU Leuven; KU Leuven; University Hospital, Antwerp; Research...

Completed

Treatment of Gait Disorders in Children With Dravet Syndrome (T-GaiD)

Dravet Syndrome | Severe Myoclonic Epilepsy of Infancy

Belgium
Eisai Limited

Terminated

Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy

Epilepsy

Australia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
Eisai Inc.

Recruiting

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)

Epilepsies, Myoclonic

United States, Canada
NYU Langone Health
PTC Therapeutics

Completed

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

Epilepsy

United States
Biocodex

Recruiting

Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA

Dravet Syndrome

United States
Epygenix

Completed

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Dravet Syndrome

United States
University of Colorado, Denver
Denver Health Medical Center

Completed

Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population

Dravet Syndrome

United States
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (UK Only)

Dravet Syndrome

United Kingdom
Boston Children's Hospital
Encoded Therapeutics

Recruiting

Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome

Dravet Syndrome

United States
Stoke Therapeutics, Inc

Completed

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

Dravet Syndrome

United States
Fondazione Policlinico Universitario Agostino Gemelli...
IRCCS San Raffaele

Enrolling by invitation

EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity (EXEDRA)

Dravet Syndrome

Italy
Zogenix International Limited, Inc., a subsidiary...

Completed

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

Dravet Syndrome

United States, United Kingdom, Spain, Belgium, Italy, Australia, Denmark, Germany, Canada, Japan, Netherlands, France
Gillette Children's Specialty Healthcare
Mayo Clinic; Dartmouth-Hitchcock Medical Center; Ann & Robert H Lurie Children...

Completed

Verapamil as Therapy for Children and Young Adults With Dravet Syndrome

Dravet Syndrome

United States
University of California, Los Angeles

Available

Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol) (Dravet)

Dravet Syndrome

United States
Encoded Therapeutics

Terminated

Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies (ENVISION)

Dravet Syndrome

United States, Spain, Australia, United Kingdom
Eisai Inc.

Available

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Epilepsies, Myoclonic | Drug Resistant Epilepsy
UCB BIOSCIENCES, Inc.

Recruiting

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome (ORCHID)

Dravet Syndrome

United States
Cook Children's Health Care System
Encoded Therapeutics

Recruiting

GABA Biomarkers in Dravet Syndrome

Dravet Syndrome

United States
Hospices Civils de Lyon

Recruiting

Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome (AUTONOMIC)

Epilepsy | Dravet Syndrome

Belgium, France, Germany
Stoke Therapeutics, Inc

Enrolling by invitation

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Dravet Syndrome

United States
Fondation Ophtalmologique Adolphe de Rothschild

Completed

Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome (EXCIDRAH)

Dravet Syndrome

France
Jazz Pharmaceuticals

Completed

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Epilepsy | Dravet Syndrome

France, United States, United Kingdom, Poland
INSYS Therapeutics Inc

Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Dravet Syndrome
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Dravet Syndrome

Australia
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome (ENDEAVOR)

Dravet Syndrome

United States
Epygenix
Forest Hills Lab; Liberyx Therapeutics

Recruiting

EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome (ARGUS)

Dravet Syndrome

United States, Canada, Spain, Georgia, Hungary
Zogenix, Inc.

Approved for marketing

ZX008 Expanded Access Protocol

Dravet Syndrome
Zogenix International Limited, Inc., a subsidiary...

Completed

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

Dravet Syndrome

United States, France, United Kingdom, Canada, Germany, Netherlands, Spain
Jazz Pharmaceuticals

Completed

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

Epilepsy | Dravet Syndrome

United States, United Kingdom
Jazz Pharmaceuticals

Completed

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Epilepsy | Dravet Syndrome

United States, Spain, Israel, Poland, Australia, Netherlands
University of Colorado, Denver

No longer available

Compassionate Use of Stiripentol in Dravet Syndrome

Dravet Syndrome

United States
Children's Hospital Medical Center, Cincinnati

Approved for marketing

Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome

Dravet Syndrome

United States
H. Lundbeck A/S

Terminated

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Dravet Syndrome

United States, Mexico
H. Lundbeck A/S

Withdrawn

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Dravet Syndrome

United States, Mexico
Mayo Clinic

No longer available

Stiripentol in Dravet Syndrome

Dravet Syndrome

United States
Eye Hospital Pristina Kosovo

Enrolling by invitation

Human Fresh Corneal Lenticule Implantation Criteria in Progressive Corneal Disease Using Relex-Smile (Relex-Smile)

Progressive Disease of Corneae

Kosovo

Clinical Trials on Myoclonic Epilepsies, Progressive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations